BRPI0416227A - micropartìculas compreendendo análogos de somatostatina - Google Patents

micropartìculas compreendendo análogos de somatostatina

Info

Publication number
BRPI0416227A
BRPI0416227A BRPI0416227-7A BRPI0416227A BRPI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A
Authority
BR
Brazil
Prior art keywords
microparticles
somatostatin analogs
somatostatin
biocompatible
understanding
Prior art date
Application number
BRPI0416227-7A
Other languages
English (en)
Inventor
Markus Ahlheim
Michael Ausborn
Olivier Lambert
Marc Riemen-Schnitter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0326602A external-priority patent/GB0326602D0/en
Priority claimed from GB0406241A external-priority patent/GB0406241D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416227A publication Critical patent/BRPI0416227A/pt
Publication of BRPI0416227B1 publication Critical patent/BRPI0416227B1/pt
Publication of BRPI0416227B8 publication Critical patent/BRPI0416227B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

"MICROPARTìCULAS COMPREENDENDO ANáLOGOS DE SOMATOSTATINA". A presente invenção refere-se a micropartículas compreendendo um análogo de somatostatina incrustadas em uma matriz polimérica biocompatível e farmacologicamente aceitável para uma liberação de longa ação e composições farmacêuticas compreendendo essas micropartículas.
BRPI0416227A 2003-11-14 2004-11-12 micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit BRPI0416227B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0326602.0 2003-11-14
GB0326602A GB0326602D0 (en) 2003-11-14 2003-11-14 Organic compounds
GB0406241.0 2004-03-19
GB0406241A GB0406241D0 (en) 2004-03-19 2004-03-19 Organic compounds
PCT/EP2004/012870 WO2005046645A1 (en) 2003-11-14 2004-11-12 Microparticles comprising somatostatin analogues

Publications (3)

Publication Number Publication Date
BRPI0416227A true BRPI0416227A (pt) 2007-01-02
BRPI0416227B1 BRPI0416227B1 (pt) 2019-06-18
BRPI0416227B8 BRPI0416227B8 (pt) 2021-05-25

Family

ID=34593737

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416227A BRPI0416227B8 (pt) 2003-11-14 2004-11-12 micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit

Country Status (30)

Country Link
US (3) US7759308B2 (pt)
EP (1) EP1686964B9 (pt)
JP (1) JP4682145B2 (pt)
KR (1) KR101233892B1 (pt)
AR (1) AR047310A1 (pt)
AT (1) ATE455537T1 (pt)
AU (1) AU2004289055C1 (pt)
BR (1) BRPI0416227B8 (pt)
CA (1) CA2541944C (pt)
CY (2) CY1110293T1 (pt)
DE (1) DE602004025271D1 (pt)
DK (1) DK1686964T3 (pt)
EC (1) ECSP066565A (pt)
ES (1) ES2339026T3 (pt)
HR (1) HRP20100190T1 (pt)
IL (1) IL175286A (pt)
IS (1) IS8480A (pt)
LU (1) LU92701I2 (pt)
MA (1) MA28155A1 (pt)
MX (1) MXPA06005357A (pt)
MY (1) MY158342A (pt)
NO (2) NO337172B1 (pt)
NZ (1) NZ546788A (pt)
PE (1) PE20050581A1 (pt)
PL (1) PL1686964T3 (pt)
PT (1) PT1686964E (pt)
RU (1) RU2404749C2 (pt)
SI (1) SI1686964T1 (pt)
TW (1) TWI295178B (pt)
WO (1) WO2005046645A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
KR20130024988A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
CN101677952B (zh) * 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
CA2713339C (en) * 2008-01-30 2017-01-17 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
AU2009232000B2 (en) 2008-04-03 2014-12-11 Baxter International Inc. Hemostatic microspheres
US9314508B2 (en) 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2890760A4 (en) 2012-08-30 2016-10-12 Atrp Solutions Inc DOUBLE MECHANISM THICKENERS FOR HYDRAULIC FRACKING FLUIDS
EP2951220B1 (en) 2013-02-04 2020-11-25 Pilot Polymer Technologies, Inc. Salt-tolerant star macromolecules
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
MX385886B (es) 2014-07-03 2025-03-18 Pilot Polymer Tech Inc Macromoleculas estrellas compatibles con tensoactivos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
AU4964699A (en) * 1998-07-23 2000-02-14 Biomeasure Incorporated Encapsulation of water soluble peptides
JP4303438B2 (ja) 1999-08-18 2009-07-29 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ペプチドの持続放出製剤
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP4679822B2 (ja) * 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
CA2541944A1 (en) 2005-05-26
RU2404749C2 (ru) 2010-11-27
BRPI0416227B1 (pt) 2019-06-18
EP1686964B9 (en) 2010-08-04
US20100272809A1 (en) 2010-10-28
US8188037B2 (en) 2012-05-29
CY1110293T1 (el) 2015-01-14
US7759308B2 (en) 2010-07-20
ES2339026T3 (es) 2010-05-14
AU2004289055B2 (en) 2008-10-30
PT1686964E (pt) 2010-02-04
ECSP066565A (es) 2006-10-17
MXPA06005357A (es) 2006-07-10
DE602004025271D1 (de) 2010-03-11
CY2015011I1 (el) 2016-04-13
NO20062777L (no) 2006-08-14
JP4682145B2 (ja) 2011-05-11
PL1686964T3 (pl) 2010-06-30
IS8480A (is) 2006-05-23
KR20060115873A (ko) 2006-11-10
TWI295178B (en) 2008-04-01
JP2007511482A (ja) 2007-05-10
IL175286A (en) 2012-05-31
ATE455537T1 (de) 2010-02-15
KR101233892B1 (ko) 2013-02-18
NO2016003I2 (no) 2016-02-02
BRPI0416227B8 (pt) 2021-05-25
EP1686964A1 (en) 2006-08-09
HK1093682A1 (en) 2007-03-09
TW200529883A (en) 2005-09-16
PE20050581A1 (es) 2005-09-09
LU92701I2 (fr) 2015-11-02
US20120214749A1 (en) 2012-08-23
WO2005046645A1 (en) 2005-05-26
DK1686964T3 (da) 2010-05-17
CY2015011I2 (el) 2016-04-13
AR047310A1 (es) 2006-01-18
AU2004289055C1 (en) 2009-05-21
NO337172B1 (no) 2016-02-01
NZ546788A (en) 2009-12-24
SI1686964T1 (sl) 2010-05-31
AU2004289055A1 (en) 2005-05-26
HRP20100190T1 (hr) 2010-06-30
IL175286A0 (en) 2006-09-05
EP1686964B1 (en) 2010-01-20
NO2016003I1 (no) 2016-02-02
CA2541944C (en) 2014-02-25
MY158342A (en) 2016-09-30
MA28155A1 (fr) 2006-09-01
RU2006120484A (ru) 2007-12-27
US20070212418A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
BRPI0416227B8 (pt) micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit
HRP20090381T1 (en) Compositions comprising drospirenone molecularly dispersed
PT2341142E (pt) Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo
EP1469840A4 (en) PROLONGED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORINE
DK1467724T3 (da) Farmaceutisk sammensætning med agomelatin til dispergering i mundhulen
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
AP2006003844A0 (en) Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
TWI319318B (en) Modified release pharmaceutical formulation
AU2003260803A8 (en) Sustained release pharmaceutical composition
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
BR0212298A (pt) Composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
PL376015A1 (en) Pharmaceutical composition comprising octreotide microparticles
NO20062111L (no) 2-(3,4-dimetylfenyl)-4-{[2-hydroksy-3'(1H-tetrazol-5-yl)]-hydrazon}-5-metyl-2,4-dihydropyrozol-3-on kolin.
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
ATE448780T1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
BRPI0408848A (pt) formulações orais de cladribine
PL370162A1 (en) Orodispersible pharmaceutical composition comprising perindopril
BRPI0411820A (pt) composição farmacêutica
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
TNSN06136A1 (en) Microparticles comprising somatostatin analogues
TNSN05310A1 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
ITMI20021127A1 (it) Composizioni farmaceutiche oromucosali
SI1467750T1 (sl) Farmacevtski sestavek perindoprila disperzen v ustih (orodisperzen)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/16 , A61K 38/31

Ipc: A61K 38/31 (2006.01), A61K 9/16 (2006.01), A61P 5/

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: RECORDATI AG (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.